1. Home
  2. PDEX vs ACTU Comparison

PDEX vs ACTU Comparison

Compare PDEX & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDEX
  • ACTU
  • Stock Information
  • Founded
  • PDEX 1978
  • ACTU 2015
  • Country
  • PDEX United States
  • ACTU United States
  • Employees
  • PDEX N/A
  • ACTU N/A
  • Industry
  • PDEX Medical/Dental Instruments
  • ACTU
  • Sector
  • PDEX Health Care
  • ACTU
  • Exchange
  • PDEX Nasdaq
  • ACTU NYSE
  • Market Cap
  • PDEX 161.1M
  • ACTU 153.1M
  • IPO Year
  • PDEX N/A
  • ACTU 2024
  • Fundamental
  • Price
  • PDEX $48.56
  • ACTU $6.74
  • Analyst Decision
  • PDEX Strong Buy
  • ACTU
  • Analyst Count
  • PDEX 1
  • ACTU 0
  • Target Price
  • PDEX $52.00
  • ACTU N/A
  • AVG Volume (30 Days)
  • PDEX 36.8K
  • ACTU 73.4K
  • Earning Date
  • PDEX 02-06-2025
  • ACTU 11-13-2024
  • Dividend Yield
  • PDEX N/A
  • ACTU N/A
  • EPS Growth
  • PDEX 1.56
  • ACTU N/A
  • EPS
  • PDEX 1.49
  • ACTU N/A
  • Revenue
  • PDEX $56,798,000.00
  • ACTU N/A
  • Revenue This Year
  • PDEX $15.56
  • ACTU N/A
  • Revenue Next Year
  • PDEX $3.28
  • ACTU N/A
  • P/E Ratio
  • PDEX $32.78
  • ACTU N/A
  • Revenue Growth
  • PDEX 21.01
  • ACTU N/A
  • 52 Week Low
  • PDEX $16.18
  • ACTU $5.51
  • 52 Week High
  • PDEX $54.84
  • ACTU $10.16
  • Technical
  • Relative Strength Index (RSI)
  • PDEX 49.20
  • ACTU N/A
  • Support Level
  • PDEX $45.00
  • ACTU N/A
  • Resistance Level
  • PDEX $49.68
  • ACTU N/A
  • Average True Range (ATR)
  • PDEX 3.48
  • ACTU 0.00
  • MACD
  • PDEX -1.10
  • ACTU 0.00
  • Stochastic Oscillator
  • PDEX 13.72
  • ACTU 0.00

About PDEX Pro-Dex Inc.

Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: